Immuron Ltd (IMC) - Total Assets
Based on the latest financial reports, Immuron Ltd (IMC) holds total assets worth AU$15.14 Million AUD (≈ $10.71 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net asset quality index of Immuron Ltd to measure how much of total assets are equity-financed.
Immuron Ltd - Total Assets Trend (2000–2025)
This chart illustrates how Immuron Ltd's total assets have evolved over time, based on quarterly financial data. Explore IMC long-term investments to assets to see how much of total assets are deployed in long-term investments.
Immuron Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Immuron Ltd's total assets of AU$15.14 Million consist of 98.9% current assets and 1.1% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 27.9% |
| Accounts Receivable | AU$791.39K | 7.8% |
| Inventory | AU$1.77 Million | 17.5% |
| Property, Plant & Equipment | AU$113.95K | 1.1% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Immuron Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IMC market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immuron Ltd's current assets represent 98.9% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 27.9% of total assets in 2025, up from 7.9% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 17.5% of total assets.
Immuron Ltd Competitors by Total Assets
Key competitors of Immuron Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Hugel Inc
KQ:145020
|
Korea | ₩1.13 Trillion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Immuron Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.04 | 6.80 | 55.64 |
| Quick Ratio | 6.83 | 5.92 | 54.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$13.07 Million | AU$10.03 Million | AU$26.80 Million |
Immuron Ltd - Advanced Valuation Insights
This section examines the relationship between Immuron Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | -34.9% |
| Total Assets | AU$10.13 Million |
| Market Capitalization | $6.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Immuron Ltd's assets below their book value (0.68x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Immuron Ltd's assets decreased by 34.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Immuron Ltd (2000–2025)
The table below shows the annual total assets of Immuron Ltd from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$10.13 Million ≈ $7.17 Million |
-34.86% |
| 2024-06-30 | AU$15.55 Million ≈ $11.00 Million |
-29.28% |
| 2023-06-30 | AU$21.99 Million ≈ $15.56 Million |
-11.54% |
| 2022-06-30 | AU$24.86 Million ≈ $17.59 Million |
-8.12% |
| 2021-06-30 | AU$27.05 Million ≈ $19.14 Million |
+336.19% |
| 2020-06-30 | AU$6.20 Million ≈ $4.39 Million |
-27.56% |
| 2019-06-30 | AU$8.56 Million ≈ $6.06 Million |
-7.37% |
| 2018-06-30 | AU$9.24 Million ≈ $6.54 Million |
+11.54% |
| 2017-06-30 | AU$8.29 Million ≈ $5.86 Million |
-6.13% |
| 2016-06-30 | AU$8.83 Million ≈ $6.25 Million |
+46.67% |
| 2015-06-30 | AU$6.02 Million ≈ $4.26 Million |
-21.14% |
| 2014-06-30 | AU$7.63 Million ≈ $5.40 Million |
+202.07% |
| 2013-06-30 | AU$2.53 Million ≈ $1.79 Million |
-30.55% |
| 2012-06-30 | AU$3.64 Million ≈ $2.57 Million |
+36.77% |
| 2011-06-30 | AU$2.66 Million ≈ $1.88 Million |
-29.96% |
| 2010-06-30 | AU$3.80 Million ≈ $2.69 Million |
+670.42% |
| 2009-06-30 | AU$493.03K ≈ $348.85K |
-74.05% |
| 2008-06-30 | AU$1.90 Million ≈ $1.34 Million |
-42.36% |
| 2007-06-30 | AU$3.30 Million ≈ $2.33 Million |
-50.25% |
| 2006-06-30 | AU$6.63 Million ≈ $4.69 Million |
-17.75% |
| 2005-06-30 | AU$8.05 Million ≈ $5.70 Million |
+64.06% |
| 2004-06-30 | AU$4.91 Million ≈ $3.47 Million |
-17.55% |
| 2003-06-30 | AU$5.96 Million ≈ $4.21 Million |
-9.45% |
| 2002-06-30 | AU$6.58 Million ≈ $4.65 Million |
-16.02% |
| 2001-06-30 | AU$7.83 Million ≈ $5.54 Million |
+73.92% |
| 2000-06-30 | AU$4.50 Million ≈ $3.19 Million |
-- |
About Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more